Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1695-1696
DOI: 10.1111/apt.70663 ↗Kurz gefasst
Leserbrief in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 07.04.2026. Verfasst von Alessandro Granito und 2 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Center for the Study and Treatment of Autoimmune Diseases of the Liver and Biliary System, University of Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, Italy.
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Bologna, Italy.
- Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Division of Internal Medicine, Morgagni-Pierantoni Hospital, Forlì, Italy.
ORCID-Profile: Alessandro Granito
Zitieren
APA
Granito, A., Pappas, G., & Muratori, P. (2026). Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?. Alimentary Pharmacology & Therapeutics, 63(12), 1695-1696. https://doi.org/10.1111/apt.70663
Vancouver
Granito A, Pappas G, Muratori P. Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?. Alimentary Pharmacology & Therapeutics. 2026;63(12):1695-1696. doi:10.1111/apt.70663
BibTeX
@article{Granito2026,
author = {Granito, Alessandro and Pappas, Georgios and Muratori, Paolo},
title = {Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {12},
pages = {1695--1696},
doi = {10.1111/apt.70663}
}
EUVIMED